Ambrisentan for early mild pulmonary arterial hypertension
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a drug called ambrisentan for people with very early, low-risk pulmonary arterial hypertension (PAH). If you have a mild form of PAH and haven't yet taken other PAH medications, this trial might help slow the progression of your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your pulmonary artery pressure should be between 20 and 25 mmHg, and your pulmonary vascular resistance between 2 and 3 Wood units.
- You must have one of these types of pulmonary arterial hypertension: idiopathic, heritable, drug/toxin-induced, or associated with connective tissue disease, portal hypertension, or congenital heart disease.
- You must be at low risk according to current guidelines for pulmonary hypertension.
- You must not have taken any PAH-specific medications before this trial (except occasional use of erectile dysfunction medication).
- You must not have certain other conditions like severe anemia, kidney problems, or liver issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.